Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use OMEPRAZOLE AND SODIUM BICARBONATE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE AND SODIUM BICARBONATE CAPSULES. OMEPRAZOLE and SODIUM BICARBONATE capsules for oral use Initial U.S. Approval: 2004
Medication labelWhy this: Advisory · dailymed-prescription
Omeprazole and sodium bicarbonate capsules are indicated for short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. [See Clinical Studies (14.1)] Omeprazole and sodium bicarbonate capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer. [See Clinical Studies (14.2)] Symptomatic GERD Omeprazole and sodium bicarbonate capsules are indicated for the treatment of heartburn and other symptoms associated with GERD. [See Clinical Studies (14.3)] Erosive Esophagitis Omeprazole and sodium bicarbonate capsules are indicated for the short-term treatment (4 to 8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. The efficacy of omeprazole and sodium bicarbonate used for longer than 8 weeks in these patients has not been established. If a patient does not respond to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. If there is recurrence of erosive esophagitis or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole and sodium bicarbonate may be considered. [See Clinical Studies (14.3)] Omeprazole and sodium bicarbonate capsules are indicated to maintain healing of erosive esophagitis. Controlled studies do not extend beyond 12 months. [See Clinical Studies (14.4) ]
- generic_name
- omeprazole and sodium bicarbonate
- product_names
- Omeprazole and Sodium Bicarbonate
- ndc
- 13107-115, 13107-116, 13107-115-30, 13107-115-05, 13107-116-30, 13107-116-05
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en